FDA Approves Belzutifan for Pheochromocytoma or Paraganglioma By Ogkologos - June 6, 2025 613 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LITESPARK-015 study Source RELATED ARTICLESMORE FROM AUTHOR Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe EMA Recommends Extension of Therapeutic Indications for Ponatinib MOST POPULAR How Wartime Violence Against Women Is Hurting Millions Worldwide August 2, 2021 Announcing ‘Cancer Revolution’ – a world-first exhibition to engage people with... July 28, 2021 Mapping Cancer Genomic Evolution Offers Insights into Tumor Development March 6, 2020 Berry Recipes August 14, 2020 Load more HOT NEWS Pediatricians’ Offices Can Help Parents Quit Smoking, Study Shows Bladder Cancer Trial Finds Extended Lymph Node Surgery Doesn’t Improve Survival Cancer Won’t Wait: “I prayed she would see her daughter start... EMA Recommends Granting a Conditional Marketing Authorisation for Talquetamab
